Added to YB: 2026-04-07
Pitch date: 2026-04-04
GSK [neutral]
GSK plc
Author Info
No bio for this author
Company Info
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
Market Cap
GBP 85.7B
Pitch Price
N/A
Price Target
N/A
Dividend
3.36%
EV/EBITDA
8.63
P/E
15.45
EV/Sales
3.05
Sector
Pharmaceuticals
Category
value
Stocks Update 3/4/2026: GSK – Pipeline progress; ViiV update
GSK (update): Depemokimab approved in China for severe asthma (2M+ patients); bepirovirsen accepted for regulatory review as potential first-in-class functional cure for chronic hep B (75M+ patients). Pfizer exited ViiV; Shionogi now 21.7%, GSK 78.3%; deal brings GSK $1.875B. Trades 11.9x fwd P/E.
Read full article (1 min)